00:00
00:00
00:00
Scancell Holdings - Synergy of SCIB1 with checkpoint inhibitors

Scancell Holdings plc is pleased to announce new data demonstrating that animals treated with a combination of SCIB1, Scancell's ImmunoBody? vaccine in development for the treatment of melanoma, and checkpoint inhibition (blockade of the PD-1 immune checkpoint pathway), showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Dr Richard Goodfellow
Joint Chief Executive Officer

Company Events - SCANCELL HOLDINGS